Merck hands back preclinical Parkinson's disease assets to Addex

Addex Pharmaceuticals, the Swiss biotech, has found itself once again a potential innocent bystander in the integration of Merck & Co and Schering-Plough. On 2 September, just after the markets had closed, Addex announced that Merck had opted not to continue developing orally available positive allosteric modulators (PAM) targeting the metabotropic glutamate receptor 4 (mGluR4) as potential treatments for Parkinson's disease and other undisclosed indications.

More from Neurological

More from Therapeutic Category